# Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

> **NCT04187560** · PHASE1 · COMPLETED · sponsor: **LB Pharmaceuticals Inc.** · enrollment: 64 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** LB-102

## Key facts

- **NCT ID:** NCT04187560
- **Lead sponsor:** LB Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-22
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-11-09
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04187560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04187560, "Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04187560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*